MoneyWorks4Me

Check Before You Invest : Parnax Lab Ltd

BSE: 506128 NSE: PARNAXLAB ISIN: INE383L01019
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Parnax Lab Ltd belong to?
Parnax Lab Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Parnax Lab Ltd a good quality company?
Parnax Lab Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q.3 Is Parnax Lab Ltd undervalued or overvalued?
Parnax Lab Ltd appears Overvalued, as its key valuation ratios are higher than their past averages.

Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more.

Valuation Ratios Current 5-year
Historic Median
Price to Earnings 14.19 77.69
Price to Book 1.33 5.61
Price to Sales 0.5 15.72
EV to EBITDA 7.14 62.78
Q.4 Is Parnax Lab Ltd a good buy now?
Parnax Lab Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

A: What are the trends in revenue and profit margins?

Q.1 Revenue growth of Parnax Lab Ltd?
Parnax Lab Ltd revenue growth is 32.4% for FY-2026, which is above its 5-year CAGR of 22.51%, indicating faster growth.

Q.2 Gross Profit margin of Parnax Lab Ltd?
Parnax Lab Ltd Gross profit margin which is the profit after deduction of direct costs, is 10.2% for FY-2026, which is below its 5-year median of 11.1%, indicating decreasing margins.

Q.3 Operating Profit Margin of Parnax Lab Ltd?
Parnax Lab Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 10.96% for FY-2026, which is below its 5-year median of 13.75% indicating decreasing margins.

Q.4 Net Profit Margin of Parnax Lab Ltd?
Parnax Lab Ltd Net Profit Margin is 4.75% for FY-2026, is below its 5-year median of 5.1%, indicating decreasing margins.
Current Level 5-year
Historic Median
Gross Profit Margin (%) 10.2 11.1
Operating Profit Margin (%) 10.96 13.75
Net Profit Margin (%) 4.75 5.1

B: Does the business utilize capital efficiently?

Q.5 Return on Asset of Parnax Lab Ltd?
Parnax Lab Ltd Return on Asset is 5.65%, which is in line with its 5-year historical median of 5.78%, indicating stable asset utilization efficiency.

Q.6 Return on capital employed (ROCE) of Parnax Lab Ltd?
Parnax Lab Ltd Return on capital employed is 13.79% for FY-2026, which is below its 5-year historical median of 14.71%. The current ROCE is below its estimated weighted average cost of capital (WACC) of 14%, indicating value preservation.

Q.7 Return on Equity (ROE) of Parnax Lab Ltd?
Parnax Lab Ltd Return on equity is 13.24% for FY-2026, which is below its 5-year historical median of 14.92%, indicating the business is making worse use of its shareholders capital.

Q.8 Cash conversion cycle of Parnax Lab Ltd?
Parnax Lab Ltd Cash conversion cycle is 51 days, below its 5-year historical median of 64 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level 5-year
Historic Median
Asset Turnover (x) 1.19 1.13
ROE (%) 13.24 14.92
ROCE (%) 13.79 14.71
Cash Conversion Cycle 51 days 64 days

C: How much debt does the business have and is it at a sustainable level?

Q.9 Debt to Equity ratio of Parnax Lab Ltd?
Parnax Lab Ltd Debt-to-Equity ratio is 0.78, which is above the industry average of 0.14, indicating higher debt levels in the industry.

Q.10 Debt to cash flow from operations of Parnax Lab Ltd?
Parnax Lab Ltd Debt to cash flow from operations is 9.31, which is at a unhealthy level.

Ownership & governance

D: Promoter shareholding and pledge status of Parnax Lab Ltd?

Q.1 Promoter shareholding and pledge status of Parnax Lab Ltd?
Promoters hold 72.30% of the Parnax Lab Ltd, with 9.41% of their stake pledged, indicating low pledge risk.

Peer comparison (industry-wise, mcap)

E: How does Parnax Lab Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Parnax Lab Ltd vs industry peers?
Parnax Lab Ltd revenue CAGR is 22.51%, compared to the industry median CAGR of 0.00%, indicating faster growth and gaining its market share.
Profit Metrics
Current Level 5-year
Industry Median
Revenue Growth (%) 32.4 0
Gross Profit Growth (%) 8.7 11.1
Operating Profit Growth (%) - 8.9
Net Profit Growth (%) - 12.5
Operating Efficiency
Current Level 5-year
Industry Median
Asset Turnover (x) 1.19 0.74
ROE (%) 13.24 8.93
ROCE (%) 13.79 10.95
Cash Conversion Cycle (days) 50.93 81

Valuation & price assessment

Q.1 Stock return of Parnax Lab Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 10.5% based on the current price.
9Y 5Y 3Y 1Y
Share Price
CAGR
10.5% 35.1% 4.8% -10%
Q.2 Valuation ratios of Parnax Lab Ltd vs historical?
The current P/E ratio of 14.19 is lower than its historical median of 77.69, indicating that the stock is trading below its historical average valuation.
Q.3 How do the current valuation ratios compare with 5-year historical median and industry numbers?
Valuation Ratios Current 5-year
Historic Median
5-year
Industry Median
Price to Earnings 14.19 77.69 29.21
Price to Book 1.33 5.61 2.86
Price to Sales 0.5 15.72 2.70
EV to EBITDA 7.14 62.78 15.83

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: